Evolus Retained Earnings (Accumulated Deficit) 2016-2024 | EOLS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Evolus retained earnings (accumulated deficit) from 2016 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

Evolus Retained Earnings (Accumulated Deficit) 2016-2024 | EOLS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Evolus retained earnings (accumulated deficit) from 2016 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$203.2B
Stryker (SYK)	$148.2B
Boston Scientific (BSX)	$133.1B
EssilorLuxottica (ESLOY)	$113.5B
Medtronic (MDT)	$109B
Haleon (HLN)	$42.9B
Lonza Group Ag (LZAGY)	$42.1B
GE HealthCare Technologies (GEHC)	$37.7B
ResMed (RMD)	$35B
Terumo (TRUMY)	$29.2B
Koninklijke Philips (PHG)	$24.4B
Zimmer Biomet Holdings (ZBH)	$22.1B
Insulet (PODD)	$18.4B
Baxter (BAX)	$16.6B
Smith & Nephew SNATS (SNN)	$11.2B
BellRing Brands (BRBR)	$9.5B
Bio-Rad Laboratories (BIO)	$9B
Demant (WILYY)	$8.3B
Lantheus Holdings (LNTH)	$5.5B
TG Therapeutics (TGTX)	$4.7B
Haemonetics (HAE)	$4.3B
ICU Medical (ICUI)	$4.2B
Prestige Consumer Healthcare (PBH)	$4.1B
Perrigo (PRGO)	$3.7B
Envista Holdings (NVST)	$3.5B
Neogen (NEOG)	$3.3B
Agios Pharmaceuticals (AGIO)	$3.1B
Shandong Weigao Medical Polymer (SHWGF)	$3B
GN Store Nord (GNNDY)	$2.8B
QuidelOrtho (QDEL)	$2.6B